JPWO2019145897A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019145897A5 JPWO2019145897A5 JP2020540345A JP2020540345A JPWO2019145897A5 JP WO2019145897 A5 JPWO2019145897 A5 JP WO2019145897A5 JP 2020540345 A JP2020540345 A JP 2020540345A JP 2020540345 A JP2020540345 A JP 2020540345A JP WO2019145897 A5 JPWO2019145897 A5 JP WO2019145897A5
- Authority
- JP
- Japan
- Prior art keywords
- container
- shell
- powder
- composition according
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 37
- 239000000843 powder Substances 0.000 claims description 32
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 229940112141 dry powder inhaler Drugs 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000012377 drug delivery Methods 0.000 claims description 2
- 238000007496 glass forming Methods 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622464P | 2018-01-26 | 2018-01-26 | |
| US62/622,464 | 2018-01-26 | ||
| PCT/IB2019/050607 WO2019145897A1 (en) | 2018-01-26 | 2019-01-24 | High dose delivery of inhaled therapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510723A JP2021510723A (ja) | 2021-04-30 |
| JPWO2019145897A5 true JPWO2019145897A5 (https=) | 2022-01-19 |
| JP2021510723A5 JP2021510723A5 (https=) | 2022-01-19 |
Family
ID=65635769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540345A Pending JP2021510723A (ja) | 2018-01-26 | 2019-01-24 | 吸入型治療薬の高用量送達 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210069106A1 (https=) |
| EP (1) | EP3743045A1 (https=) |
| JP (1) | JP2021510723A (https=) |
| KR (1) | KR20200115560A (https=) |
| CN (1) | CN111526870A (https=) |
| AR (1) | AR114308A1 (https=) |
| AU (2) | AU2019212586C1 (https=) |
| BR (1) | BR112020014793A2 (https=) |
| CA (1) | CA3089439A1 (https=) |
| CL (1) | CL2020001939A1 (https=) |
| IL (1) | IL276241A (https=) |
| MX (1) | MX2020007745A (https=) |
| RU (1) | RU2020127882A (https=) |
| WO (1) | WO2019145897A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12233177B2 (en) | 2019-09-16 | 2025-02-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
| LT4051708T (lt) | 2019-10-28 | 2025-04-10 | Medimmune Limited | Užkrūčio liaukos stromos limfopoetiną (tslp) surišančių antikūnų sausų miltelių pavidalo vaisto formos ir jų panaudojimo būdai |
| CN119306869B (zh) * | 2024-12-13 | 2025-05-16 | 万华化学集团股份有限公司 | 一种乙烯/α-烯烃共聚物及其制备方法、采用其的封装胶膜 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037303A1 (en) | 2001-11-01 | 2003-05-08 | Nektar Therapeutics | Spray drying methods and compositions thereof |
| MXPA05007154A (es) | 2002-12-30 | 2005-09-21 | Nektar Therapeutics | Atomizador prepeliculizacion. |
| KR20130066695A (ko) * | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| EP2076242B8 (en) * | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| TR200907236A2 (tr) * | 2009-09-23 | 2011-04-21 | Bi̇lgi̇ç Mahmut | Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması. |
| JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| CN107596518B (zh) * | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| WO2014144364A1 (en) * | 2013-03-15 | 2014-09-18 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
| US20180303753A1 (en) * | 2015-09-09 | 2018-10-25 | Keith Try Ung | Targeted delivery of spray-dried formulations to the lungs |
| AU2016320748B2 (en) * | 2015-09-09 | 2019-05-02 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies |
| PE20181307A1 (es) * | 2016-01-19 | 2018-08-10 | Novartis Ag | Inhalador multidosis |
| WO2017132601A1 (en) * | 2016-01-29 | 2017-08-03 | Mannkind Corporation | Dry powder inhaler |
-
2019
- 2019-01-24 EP EP19708669.7A patent/EP3743045A1/en not_active Withdrawn
- 2019-01-24 MX MX2020007745A patent/MX2020007745A/es unknown
- 2019-01-24 US US16/963,678 patent/US20210069106A1/en not_active Abandoned
- 2019-01-24 BR BR112020014793-1A patent/BR112020014793A2/pt not_active Application Discontinuation
- 2019-01-24 RU RU2020127882A patent/RU2020127882A/ru unknown
- 2019-01-24 AU AU2019212586A patent/AU2019212586C1/en not_active Ceased
- 2019-01-24 CA CA3089439A patent/CA3089439A1/en active Pending
- 2019-01-24 CN CN201980007046.7A patent/CN111526870A/zh active Pending
- 2019-01-24 JP JP2020540345A patent/JP2021510723A/ja active Pending
- 2019-01-24 KR KR1020207024324A patent/KR20200115560A/ko not_active Ceased
- 2019-01-24 WO PCT/IB2019/050607 patent/WO2019145897A1/en not_active Ceased
- 2019-01-24 AR ARP190100160A patent/AR114308A1/es not_active Application Discontinuation
-
2020
- 2020-07-23 CL CL2020001939A patent/CL2020001939A1/es unknown
- 2020-07-23 IL IL276241A patent/IL276241A/en unknown
-
2022
- 2022-04-05 AU AU2022202278A patent/AU2022202278A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6491658B2 (ja) | 熱安定性乾燥粉末医薬組成物及び方法 | |
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| EP2916826B1 (en) | Ultra low density pulmonary powders | |
| JP2009136688A (ja) | 流動抵抗調節されたエアロゾル化活性薬剤送達 | |
| CA2589118A1 (en) | A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation | |
| EP2552414A1 (en) | Pharmaceutical powder composition for inhalation | |
| JP2025061049A (ja) | 吸入可能な乾燥粉末 | |
| US20250228779A1 (en) | Method and composition for treating pulmonary fibrosis | |
| JP2021510723A5 (https=) | ||
| RU2020127882A (ru) | Доставка высоких доз ингаляционных терапевтических средств | |
| SE527200C2 (sv) | Inhalatoranordning samt kombinerade doser av formaterol och fluticason | |
| JPWO2019145897A5 (https=) | ||
| WO2014205031A1 (en) | Sustained-release formulation of rotigotine | |
| US20240180897A1 (en) | Methods and compositions for treating pulmonary hypertension | |
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| JP2025511232A (ja) | 吸入複合体及び担体ベースの製剤の組合せ | |
| WO2014205030A1 (en) | Pulmonary administration of rotigotine | |
| TW201605432A (zh) | 新穎劑量及調配物 | |
| JP2016216377A (ja) | 肺線維症の１日１回の治療 |